With continued support from Avon Foundation of Women, A&G is developing a blood test for use in detection and monitoring of breast cancer based on its proprietary biomarker GP88.
Columbia, May 6, 2013—A&G Pharmaceutical Inc., is pleased to announce that the Avon Foundation of Women has recognized the potential impact of the GP88 blood test for use in the fight against breast cancer. An award of $300,000 was presented to A&G Pharmaceutical at the 11th annual Avon Walk for Breast Cancer to raise life-saving funds and awareness for breast cancer this past weekend in Washington, D.C. It is the third such award A&G has received from the Avon Foundation and will enable A&G to continue significant progress into the clinical phase of development. This breast cancer test, based on measuring GP88 levels in the blood, will assist doctors stratify patients who are undergoing mammography examination and subsequently in monitoring disease progress during treatment.
On receiving the check from Carol Kurzig, President of the Avon Foundation for Women, Ginette Serrero, Founder and CEO of A&G Pharmaceutical stated “I am very pleased to receive support from the Avon Foundation of Women in recognition for the strides we have made as we continue to develop our proprietary GP88 blood test. The potential for this test to impact the fight against breast cancer is very real and has been one of the goals since I founded A&G. We have already developed a tissue test for identifying breast cancer patients at high risk of recurrence and the blood test in development could be used in current standard of care. In the future the two tests will be companion products for the GP88 therapeutic that we are developing at A&G”. Carol Kurzig, announced during the closing ceremony a total of $2.26 million in grants to ten local organizations, ensuring the funds raised at the Washington DC walk immediately benefit the community. “These grants represent only a portion of the funding that the Avon Foundation will distribute in the D.C. area and across the country this year, but we want to make sure that the impact of this Walk begins today,” said Kurzig.
About A&G Pharmaceutical, Inc. (www.agpharma.com)
A&G Pharmaceutical discovers, develops, and commercializes innovative personalized medicine products that improve screening, monitoring, and targeted treatment of cancer and other human diseases. A&G has discovered and patented (150 filed patents, 38 issued patents) on its unique biomarker called progranulin or “GP88.” This protein is produced by cancer cells and is required to help the cancer grow and proliferate whereas normal corresponding cells do not produce nor require progranlulin. A&G’s Precision Antibody™ service division (www.precisionantibody.com) develops and produces customized antibodies to leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G Pharmaceutical is located in Columbia, Maryland.
Avon Walk for Breast Cancer
For more information on the Avon Walk for Breast Cancer, visit www.avonwalk.org or call 888-541-WALK. To learn more about the Avon Foundation for Women visit www.avonfoundation.org. Registration is open for women and men to take part in the remaining 2013 Avon Walks in the following cities: Boston (May 18-19), Chicago (June 1-2), Santa Barbara (September 7-8), San Francisco (September 28-29), New York City (October 19-20), and Charlotte (October 26-27).